idecabtagene vicleucel
bms,2seventy bio
our initial real world experience with abecma/ide-cel car t-cell therapy . orr/cr rates similar to clinical trial data but shorter pfs. pts more heavily pretreated and with organ compromise, esp renal dysfunction. need better strategies for maintenance #mmsm #ims2022 
Hematologist/Oncologist | Myeloma Physician/Clinical Investigator | @danafarber @harvardmed #multiplemyeloma #mmsm